Immunotherapy and chemotherapy before surgery for HR-positive, HER2-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for a certain type of breast cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have breast cancer that is HR-positive (hormone receptor positive) and HER2-negative (a specific protein marker is not high).
- The tumor is considered high-risk based on its grade or low hormone receptor levels.
- The cancer is in an early stage (has not spread to distant organs) and surgery is the plan after treatment.
- You have not had chemotherapy or hormone therapy for this breast cancer before.
- You are generally healthy enough for treatment, with normal organ function and an ECOG performance status of 0 or 1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) combined with hormone therapy for breast cancer that is hormone receptor positive and HER2 negative, but did not respond well to initial chemotherapy. The goal is to see if this combination can shrink tumors before surgery and potentially improve outcomes.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This trial tests whether the drug QL1706, given before surgery, can help treat hormone receptor positive and HER2-negative breast cancer. It is for people who have not yet had cancer spread to other parts of the body.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
This study tests two immunotherapy medicines (iparomlimab and tuvonralimab) combined with radiation and standard chemotherapy for advanced head and neck cancer that cannot be removed with surgery. The goal is to see if adding these medicines helps shrink tumors and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.